Evogene Ltd. (EVGN) shareholders
Close on Nov 13, 2026Market cap $3.23MP/E 0.3Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kfir Silberman Joint filing with L.I.A. Pure Capital Ltd. (19.35%), Invest Pro Shukai Hon Ltd. (19.35%) and 1 more | 3,057,488 | 19.35% | 13D (active) amendment | Sep 8, 2026 |
| L.I.A. Pure Capital Ltd. Joint filing with Kfir Silberman (16.94%), Invest Pro Shukai Hon Ltd. (16.94%) and 1 more | 3,057,488 | 16.94% | 13D (active) amendment | Oct 6, 2026 |
| Ron Yair Peled Joint filing with L.I.A. Pure Capital Ltd. (19.35%), Kfir Silberman (19.35%) and 1 more | 3,057,488 | 19.35% | 13D (active) amendment | Aug 28, 2026 |
| Recanati Leon | 1,354,836 | 8.60% | 13D (active) amendment | Aug 4, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 1,104,906 | 9.99% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EVGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hrt Financial LP | 107,198 | 1.23% | $45.00K | New | 0.00% |
| Susquehanna International Group, Llp | 80,078 | 0.92% | $33.89K | New | 0.00% |
| Citadel Advisors LLC | 50,526 | 0.58% | $21.38K | New | 0.00% |
| XTX Topco Ltd | 19,404 | 0.22% | $8.21K | +6,683 | 0.00% |
| UBS Group AG | 10,790 | 0.12% | $4.74K | +4,438 | 0.00% |
| Daytona Street Capital LLC | 9,253 | 0.11% | $4.65K | −333 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 2,830 | 0.03% | $1.24K | −6,294 | 0.00% |
| Morgan Stanley | 1,285 | 0.01% | $564 | −2,566 | 0.00% |
| Federation des caisses Desjardins du Quebec | 500 | 0.01% | $220 | – | 0.00% |
| Osaic Holdings, Inc. | 100 | 0.00% | $44 | – | 0.00% |
| SHP Wealth Management | 65 | 0.00% | $29 | – | 0.00% |
| SBI Securities Co., Ltd. | 62 | 0.00% | $27 | −10 | 0.00% |
| Royal Bank of Canada | 42 | 0.00% | $0 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 13 | 0M | 3.2% | 3 / 2 | 4 / 5 | 0M | 0M |
| Q1 2026 | 15 | 1M | 6.1% | 2 / 1 | 5 / 5 | 0M | 0M |
| Q4 2025 | 18 | 0M | 2.1% | 5 / 1 | 7 / 1 | 0M | 0M |
| Q3 2025 | 14 | 0M | 1.8% | 1 / 3 | 5 / 3 | 0M | 0M |
| Q2 2025 | 16 | 0M | 1.5% | 4 / 6 | 2 / 4 | 0M | 0M |
| Q1 2025 | 16 | 0M | 4.8% | 3 / 5 | 3 / 2 | 0M | 0M |
| Q4 2024 | 15 | 0M | 4.6% | 5 / 5 | 1 / 4 | 0M | 0M |
| Q3 2024 | 14 | 1M | 6.3% | 14 / 0 | 0 / 0 | 1M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ofer Haviv | President and CEO, Director | – | – | Mar 18, 2026 |
| Gabi Tarcic | Chief Development Officer | 1,129 | 0.01% | Aug 26, 2026 |
| Polina Ravzin | VP Finance | – | – | Apr 9, 2026 |
| Yaron Eldad | Chief Financial Officer | 4,100 | 0.05% | Mar 18, 2026 |
| Ilia Zhidkov | Chief Technology Officer | – | – | Mar 18, 2026 |
| Adi Zuloff-Shani | Director | – | – | Oct 22, 2026 |
| Oz Adler | Director | – | – | Oct 22, 2026 |
| Adrian John Percy | Director | – | – | Sep 30, 2026 |
| Leon Recanati | Director | 1,343,886 | 15.41% | Sep 30, 2026 |
| Nir Nimrodi | Director | – | – | Sep 30, 2026 |
| Dan Michael Falk | Director | – | – | Sep 30, 2026 |
| Sarit Firon | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Leon Recanati Director | Aug 11, 2026 | Buy | +460,000 | $0.64 | $294.40K | 1,343,886 |
| Leon Recanati Director | Aug 4, 2026 | Buy | +800,000 | $0.50 | $400.00K | 883,886 |
| Gabi Tarcic Chief Development Officer | Jun 4, 2026 | Buy | +1,129 | $0.60 | $677 | 1,129 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Evogene's stock actually held short. Settlement fails (shares not delivered on time) peaked at 512,800 shares on Sep 30, 2026 over the last 90 days.
See a number that looks wrong?